No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Announcement Highlights | In the first 11 months, SUNSHINE INS's original premium income exceeded 120 billion yuan; GCL TECH plans to allot up to 1.56 billion shares, net raising approximately 1.53 billion Hong Kong dollars.
In the first 11 months, SUNSHINE INS's original premium income exceeded 120 billion yuan; the major Shareholder of CHENGDU EXPWAY won a highway project worth over 10 billion yuan.
Luye Pharma Chairman Increases Stake, Signals Confidence
LUYE PHARMA (02186.HK) has seen its Executive Chairman Liu Dianbo increase his shareholding by a total of 2 million shares.
On December 18, Gelonghui reported that LUYE PHARMA (02186.HK) announced that the company's Board of Directors was notified by Mr. Liu Dianbo, the executive director and executive chairman of the company, that on December 18, 2024, he purchased a total of 2 million shares of ordinary stock in the market through his controlled entity LUYE PHARMA Investment Limited, at an average purchase price of approximately HKD 2.2299 per share. After the purchase and as of the date of this announcement, Mr. Liu owns interests in 1,261,196,703 shares, accounting for approximately 33.53% of the total issued share capital of the company. According to Mr. Liu, he is optimistic about the company's growth, development, and future prospects.
Express News | Luye Pharma - Executive Chairman Bought 2.0 Mln Ordinary Shares of Co at Average Price of HK$2.2299 per Share on Market
Zhongtai International Starts Luye Pharma Group at Buy With HK$2.90 Price Target
